STOCK TITAN
  1. Home
  2. Sec-filings
  3. KLRS
  4. [ARS] Kalaris Therapeutics, Inc. SEC Filing

[ARS] Kalaris Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
ARS
ARS - Kalaris Therapeutics, Inc.

ARS Filing - Kalaris Therapeutics, Inc.

This filing is available as a PDF document.

Filing Type: ARS

Company: Kalaris Therapeutics, Inc. (KLRS)

Acceptance Date: 2025-07-01T07:40:26.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Kalaris Therapeutics Inc

NASDAQ:KLRS

View KLRS Stock Overview →

KLRS Rankings

#4886 Ranked by Market Cap
N/A Ranked by Dividends

KLRS Latest News

Mar 17, 2026
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Jan 28, 2026
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
Dec 17, 2025
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
Dec 17, 2025
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
Nov 24, 2025
Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

KLRS Latest SEC Filings

Mar 23, 2026
[Form 4] Kalaris Therapeutics, Inc. Insider Trading Activity
Mar 20, 2026
[144] Kalaris Therapeutics, Inc. SEC Filing
Mar 20, 2026
[Form 4] Kalaris Therapeutics, Inc. Insider Trading Activity
Mar 20, 2026
[Form 4] Kalaris Therapeutics, Inc. Insider Trading Activity
Mar 20, 2026
[Form 4] Kalaris Therapeutics, Inc. Insider Trading Activity

KLRS Stock Data

133.44M
20.58M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
BERKELEY HEIGHTS